Bolt Biotherapeutics, Inc. BOLT
Revenue compounded at +101.6% a year over five years.
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Each USD of equity lost 80 cents this year.
EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Revenue $B | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Operating income $B | −0.0 | −0.1 | −0.1 | −0.1 | −0.1 | −0.0 |
| EBITDA $B | −0.0 | −0.1 | −0.1 | −0.1 | −0.1 | −0.0 |
| Income tax $B | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Net income $B | −0.0 | −0.1 | −0.1 | −0.1 | −0.1 | −0.1 |
| Free cash flow $B | −0.0 | −0.1 | −0.1 | −0.1 | −0.1 | −0.1 |
| EPS, diluted $ | −17.85 | −33.06 | −1.83 | −2.36 | −2.97 | −28.89 |
| Dividend / sh $ | · | · | · | · | · | · |
| Payout % | · | · | · | · | · | · |
| ROE % | −79.7 | −74.3 | −48.7 | −41.8 | −135.8 | · |
| Shares out B | 0.00 | 0.00 | 0.04 | 0.04 | 0.04 | 0.00 |
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
Reconciled in 5 of 19 fiscal years. 1 of those reconciliations are divergences — the figures exist but don't fit the formula this check expects; that isn't the same as an error. 52 checks could not be computed.